In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

被引:0
作者
Aleksandra Syguła
Aleksandra Ledwon
Kornelia Hasse-Lazar
Beata Jurecka-Lubieniecka
Barbara Michalik
Ewa Paliczka-Cieślik
Marcin Zeman
Ewa Chmielik
Joanna Sczasny
Barbara Jarzab
Daria Handkiewicz-Junak
机构
[1] Maria Sklodowska-Curie National Research Institute of Oncology,Department of Nuclear Medicine and Endocrine Oncology, Gliwice Branch
[2] Maria Sklodowska-Curie National Research Institute of Oncology,The Oncologic and Reconstructive Surgery Clinic, Gliwice Branch
[3] Maria Sklodowska-Curie National Research Institute of Oncology,Tumor Pathology Department, Gliwice Branch
[4] Maria Sklodowska-Curie National Research Institute of Oncology,Radiology and Diagnostic Imaging Department, Gliwice Branch
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2022年 / 49卷
关键词
Neuroendocrine malignancies; Peptide receptor radionuclide therapy; Somatostatin analogues; Sequential treatment; Survival;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3841 / 3851
页数:10
相关论文
共 239 条
[1]  
Reubi JC(2007)Peptide receptor expression in GEP-NET [eng] Virchows Arch 48 6977-6985
[2]  
Ahlman H(1992)Aspects on diagnosis and treatment of the foregut carcinoid syndrome [eng] Scand J Gastroenterol 13 653-68
[3]  
Wängberg B(2009)ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy [eng] Neuroendocrinology 27 4656-4663
[4]  
Nilsson O(1988)Oncological applications of somatostatin analogues [eng] Cancer Res 7 373-376
[5]  
Grimelius L(1995)The somatostatin receptor family [eng] Life Sci undefined undefined-undefined
[6]  
Granérus G(2005)Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors [eng] Mayo Clin Proc undefined undefined-undefined
[7]  
Modlin IM(1990)Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors [eng] Cancer undefined undefined-undefined
[8]  
Oberg K(2001)Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours [eng] Eur J Cancer undefined undefined-undefined
[9]  
Ferone D(2002)The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol undefined undefined-undefined
[10]  
Kaltsas G(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [eng] J Clin Oncol undefined undefined-undefined